BGC > Produktsuche > Cidofovir dihydrate

Description:
Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.

• Molecular Weight:315.22
• Boiling Point:609.5°C at 760 mmHg
• Melting Point:260°C (dec)
• Purity:>98%

Molecular Formula:
C8H18N3O8P
Canonical SMILES:
C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O
InChI:
InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0./s1
InChIKey:
FPKARFMSZDBYQF-ILKKLZGPSA-N
Solubility:
Soluble in DMSO
Appearance:
White Powder
Application:
Antiviral Agents
Storage: Store at RT
Synonyms:
HPMPC dihydrate; Vistide dihydrate; (S)-HPMPC dihydrate